達安基因(002030.SZ):全資子公司收到現金分紅款46.34萬元
格隆匯9月26日丨達安基因(002030.SZ)公佈,公司全資子公司廣州市達安基因科技有限公司(以下簡稱"達安科技")近日收到其參股公司珠海雅莎生物科技股份有限公司(以下簡稱"雅莎股份")的現金分紅款,具體情況如下:根據雅莎股份2024年第三次臨時股東大會決議,其利潤分配方案為:以現有總股本41,927,609股為基數,向全體股東每10股派1.2元人民幣現金。公司全資子公司達安科技對雅莎股份持股比例約為9.21%,本次現金分紅金額為463,357.08元。
近日,公司全資子公司達安科技已收到上述現金分紅款463,357.08元。上述利潤分配將增加本公司2024年度合併報表淨利潤463,357.08元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.